Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Colon Cancer treatment details. Biologic therapy. Memorial Sloan-Kettering Cancer Center, New York, NY, United States

Survival: 4.8 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: United States
City/State/Province: New York, NY
Hospital: Memorial Sloan-Kettering Cancer Center
Journal: Link
Date: 7/2010

This phase II study involved 47 previously treated metastatic colorectal cancer patients. The median age was 62 years and 59% were male.

Patients were treated with the biologic therapy agent tremelimumab, which is an anti-CTLA4 monoclonal antibody that promotes attack of cancer cells by the immune system.

The most severe toxicity was grade 4 thrombocytopenia. Grade 3 diarrhea, fatigue, and colitis were also reported.

The median progression-free survival was 2.3 months and median overall survival was 4.8 months.

This study was supported by Pfizer, makers of tremelimumab.

Correspondence: Dr. Ki Y. Chung; email:

E-mail to a Friend Email Physician More Information